Navigation Links
Almac Discovery and Queen's launch £13M cancer drug discovery partnership

A new 13 million partnership to accelerate cancer-focused drug discovery in Northern Ireland has been launched by Enterprise Minister Arlene Foster MLA.

As part of the project, Queen's and Almac Discovery have announced the scheduling of a phase one clinical trial for ovarian cancer, involving the first novel cancer drug fully developed in Northern Ireland.

Involving up to 60 ovarian cancer patients, the drug being trialled has been created as a result of an earlier collaboration between Almac Discovery and Professor Tracy Robson from the School of Pharmacy at Queen's.

Explaining about the trial, Professor Robson said: "This latest trial involves a new treatment for cancer known as ALM201, which rather than attacking tumours directly, prevents the growth of new blood vessels in tumours, starving them of oxygen and nutrients and thereby preventing their growth. It targets tumours by an entirely different pathway to those treatments currently approved."

Alan Armstrong, CEO of Almac added: "Bringing new treatments to patients is a complex process. The announcement today of a new clinical trial, which is the result of a previous partnership between Almac and Queen's School of Pharmacy, is a timely illustration of how collaboration between the University and industry is already creating novel approaches to cancer therapy which have a very real chance of helping patients."

At today's event, Enterprise Minister Arlene Foster, said: "This significant investment in research and development will enhance collaboration between academia and industry. This will ensure the investment is maximised, that research is effectively commercialised and that ultimately, enhanced treatment solutions are made available to cancer patients.

"The fact that Almac and Queen's are engaged in such ground-breaking research here in Northern Ireland is something that we should be extremely proud of. It will reinforce our position as a leader in research and development for the health and life sciences sector."

It was also announced today that a new CCRCB/Almac Discovery joint programme in Cancer Drug Discovery will bring researchers from Queen's University Belfast's Centre for Cancer Research and Cell Biology (CCRCB) and scientists from Almac Discovery together to translate research discoveries into treatments for patients.

The two projects represent a total investment of 13M, with 7 million of support offered by Invest Northern Ireland, which includes part funding from the European Regional Development Fund.

As a result of the joint programme, 17 scientists from Almac Discovery have been seconded to Queen's CCRCB in an industry led venture. The discovery team will work to identify parts of tumours which are susceptible to treatment by cancer drugs and to then develop the new drugs to target them.

The partnership will also enable new approaches to selecting those patients who will be most likely to respond to the new drugs, and to create the technologies needed to deliver the drugs directly to the tumour site in the patient.

The new discovery programme is being led by Professor Tim Harrison, Vice President of Discovery Chemistry with Almac Discovery. As part of this partnership, Professor Harrison has been appointed McClay Chair of Medicinal Chemistry at Queen's for the next three years.

Commenting on the new partnership, he said: "While Almac Discovery and Queen's have already been successfully collaborating for a number of years, this exciting new programme is bringing together for the first time, under one roof, some of our most talented scientists. As a result we expect to see an increase in both the breadth of drug targets we are able to identify and a subsequent increase in the development of potential therapeutics for patients."


Contact: Lisa McElroy
Queen's University Belfast

Related medicine news :

1. Shapeshifting computer program will open up drug discovery for tricky disease targets
2. Vaginal Mesh Lawsuits Proceed Against Ethicon, as Bernstein Liebhard LLP Notes Order for Discovery Conferences in Federal Ethicon Litigation
3. Transvaginal Mesh Multidistrict Litigation Update: Court Issues New Pretrial Order that Moves Ethicon Inc.’s Discovery Forward, Notes Parker Waichman
4. ChanTest Announces Third User Meeting: Partnerships in Drug Discovery
5. Voices Against Brain Cancer Comments on Discovery of Nano Drug That May Aid in Treatment of Brain Tumors
6. An important discovery at the Montreal Heart Institute: A new approach to treat the most common heart valve disease in Western countries
7. Voices Against Brain Cancer Comments on Discovery of a Cause of Resistance to Therapy in Cases of Brain Cancer
8. Voices Against Brain Cancer Comments on Recent Discovery in Ongoing Brain Cancer Research
9. MessageSolution Showcases its Cloud Archiving and eDiscovery Platform at HostingCon 2013, Introduces its Enhanced MSP Partner Program
10. The Discovery House Supports Cancer Awareness and Cure
11. Laboratory Automation Market: 2017 Equipment & Software, Drug Discovery, Clinical Diagnostics, Genomics & Proteomics Analysis in New Research Reports at RnRMarketResearch
Post Your Comments:
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
Breaking Medicine Technology: